OncoSec Medical (FRA:ONMA) LT-Debt-to-Total-Asset : 0.24 (As of Jan. 2023)

View and export this data going back to 2015. Start your Free Trial

What is OncoSec Medical LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. OncoSec Medical's long-term debt to total assests ratio for the quarter that ended in Jan. 2023 was 0.24.

OncoSec Medical's long-term debt to total assets ratio increased from Jan. 2022 (0.13) to Jan. 2023 (0.24). It may suggest that OncoSec Medical is progressively becoming more dependent on debt to grow their business.

OncoSec Medical LT-Debt-to-Total-Asset Historical Data

The historical data trend for OncoSec Medical's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoSec Medical LT-Debt-to-Total-Asset Chart

OncoSec Medical Annual Data

Trend

Jul13

Jul14

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.21

0.09

0.19

OncoSec Medical Quarterly Data
	Apr18	Jul18	Oct18	Jan19	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.13	0.16	0.19	0.24	0.24

OncoSec Medical LT-Debt-to-Total-Asset Calculation

OncoSec Medical's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jul. 2022 is calculated as

LT Debt to Total Assets (A: Jul. 2022 )	=	Long-Term Debt & Capital Lease Obligation (A: Jul. 2022 )	/	Total Assets (A: Jul. 2022 )
	=	4.057	/	21.506
	=

OncoSec Medical's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jan. 2023 is calculated as

LT Debt to Total Assets (Q: Jan. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Jan. 2023 )	/	Total Assets (Q: Jan. 2023 )
	=	1.974	/	8.232
	=

OncoSec Medical (FRA:ONMA) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

OncoSec Medical LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of OncoSec Medical's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

OncoSec Medical (FRA:ONMA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoSec Medical Inc (FRA:ONMA) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

ONCSQ:USA

Address

24 North Main Street, Pennington, NJ, USA, 08534

Website

https://www.oncosec.com

OncoSec Medical Inc is a healthcare sector company. It is focused on designing, developing and commercializing gene therapies, therapeutics, and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple-negative breast cancer.

OncoSec Medical (FRA:ONMA) Headlines

No Headlines